Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1996 Nov;33(11):968–971. doi: 10.1136/jmg.33.11.968

Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

W G Cole 1, D Chan 1, C W Chow 1, J G Rogers 1, J F Bateman 1
PMCID: PMC1050795  PMID: 8950681

Abstract

The skeleton of a child with osteogenesis imperfecta type III, resulting from the substitution of glycine 586 by valine in the triple helical domain of the alpha 2 (I) chain of type I collagen, was severely porotic but contained lamellar bone and Haversian systems. From early childhood, structural failure of the bone resulted in the disruption of growth plates, progressive bone deformities, and severe growth retardation.

Full text

PDF
968

Images in this article

968Image
on p.968
969Image
on p.969
969Image
on p.969
969Image
on p.969
970Image
on p.970
970Image
on p.970

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bateman J. F., Chan D., Mascara T., Rogers J. G., Cole W. G. Collagen defects in lethal perinatal osteogenesis imperfecta. Biochem J. 1986 Dec 15;240(3):699–708. doi: 10.1042/bj2400699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bateman J. F., Hannagan M., Chan D., Cole W. G. Characterization of a type I collagen alpha 2(I) glycine-586 to valine substitution in osteogenesis imperfecta type IV. Detection of the mutation and prenatal diagnosis by a chemical cleavage method. Biochem J. 1991 Jun 15;276(Pt 3):765–770. doi: 10.1042/bj2760765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonaventure J., Cohen-Solal L., Lasselin C., Maroteaux P. A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta. Hum Genet. 1992 Aug;89(6):640–646. doi: 10.1007/BF00221955. [DOI] [PubMed] [Google Scholar]
  4. Byers P. H., Wallis G. A., Willing M. C. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet. 1991 Jul;28(7):433–442. doi: 10.1136/jmg.28.7.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cole W. G., Patterson E., Bonadio J., Campbell P. E., Fortune D. W. The clinicopathological features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by valine in the pro alpha 1 (I) chain of type I procollagen. J Med Genet. 1992 Feb;29(2):112–118. doi: 10.1136/jmg.29.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldman A. B., Davidson D., Pavlov H., Bullough P. G. "Popcorn" calcifications: a prognostic sign in osteogenesis imperfecta. Radiology. 1980 Aug;136(2):351–358. doi: 10.1148/radiology.136.2.7403509. [DOI] [PubMed] [Google Scholar]
  7. Lamande S. R., Dahl H. H., Cole W. G., Bateman J. F. Characterization of point mutations in the collagen COL1A1 and COL1A2 genes causing lethal perinatal osteogenesis imperfecta. J Biol Chem. 1989 Sep 25;264(27):15809–15812. [PubMed] [Google Scholar]
  8. Lu J., Costa T., Cole W. G. A novel G1006A substitution in the alpha 2(I) chain of type I collagen produces osteogenesis imperfecta type III. Hum Mutat. 1995;5(2):175–178. doi: 10.1002/humu.1380050212. [DOI] [PubMed] [Google Scholar]
  9. Mackay K., Lund A. M., Raghunath M., Steinmann B., Dalgleish R. SSCP detection of a Gly565Val substitution in the pro alpha 1(I) collagen chain resulting in osteogenesis imperfecta type II. Hum Genet. 1993 Jun;91(5):439–444. doi: 10.1007/BF00217768. [DOI] [PubMed] [Google Scholar]
  10. Patterson E., Smiley E., Bonadio J. RNA sequence analysis of a perinatal lethal osteogenesis imperfecta mutation. J Biol Chem. 1989 Jun 15;264(17):10083–10087. [PubMed] [Google Scholar]
  11. Sillence D. O., Barlow K. K., Cole W. G., Dietrich S., Garber A. P., Rimoin D. L. Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet. 1986 Mar;23(3):821–832. doi: 10.1002/ajmg.1320230309. [DOI] [PubMed] [Google Scholar]
  12. Sillence D. O. Craniocervical abnormalities in osteogenesis imperfecta: genetic and molecular correlation. Pediatr Radiol. 1994;24(6):427–430. doi: 10.1007/BF02011910. [DOI] [PubMed] [Google Scholar]
  13. Sillence D. O., Senn A., Danks D. M. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr;16(2):101–116. doi: 10.1136/jmg.16.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sztrolovics R., Glorieux F. H., Travers R., van der Rest M., Roughley P. J. Osteogenesis imperfecta: comparison of molecular defects with bone histological changes. Bone. 1994 May-Jun;15(3):321–328. doi: 10.1016/8756-3282(94)90295-x. [DOI] [PubMed] [Google Scholar]
  15. Sztrolovics R., Glorieux F. H., van der Rest M., Roughley P. J. Identification of type I collagen gene (COL1A2) mutations in nonlethal osteogenesis imperfecta. Hum Mol Genet. 1993 Aug;2(8):1319–1321. doi: 10.1093/hmg/2.8.1319. [DOI] [PubMed] [Google Scholar]
  16. Traub W., Arad T., Vetter U., Weiner S. Ultrastructural studies of bones from patients with osteogenesis imperfecta. Matrix Biol. 1994 Aug;14(4):337–345. doi: 10.1016/0945-053x(94)90200-3. [DOI] [PubMed] [Google Scholar]
  17. Valli M., Zolezzi F., Mottes M., Antoniazzi F., Stanzial F., Tenni R., Pignatti P., Cetta G. Gly85 to Val substitution in pro alpha 1(I) chain causes mild osteogenesis imperfecta and introduces a susceptibility to protease digestion. Eur J Biochem. 1993 Oct 1;217(1):77–82. doi: 10.1111/j.1432-1033.1993.tb18220.x. [DOI] [PubMed] [Google Scholar]
  18. Wang Q., Orrison B. M., Marini J. C. Two additional cases of osteogenesis imperfecta with substitutions for glycine in the alpha 2(I) collagen chain. A regional model relating mutation location with phenotype. J Biol Chem. 1993 Nov 25;268(33):25162–25167. [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES